Mechanisms of glucocorticoid action in bone: Implications to glucocorticoid-induced osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 10, 1996, Pages 3441-3447

  Canalis, Ernesto ^a,b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; PARATHYROID HORMONE; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; BONE DEVELOPMENT; BONE METABOLISM; BONE REMODELING; GROWTH REGULATION; HORMONE ACTION; MINERAL METABOLISM; OSTEOBLAST; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; BONE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; PHYSIOLOGY; REVIEW;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; GLUCOCORTICOIDS; HUMANS; OSTEOBLASTS; OSTEOPOROSIS;

EID: 0029821686     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.10.3441     Document Type: Article

References (85)

1. Canalis E. 1983 The hormonal and local regulation of bone formation. Endocr Rev. 4:62-77.
2. Baron R, 1993 Anatomy and ultrastructure of bone. In: Favus MJ, ed. Primer on metabolic diseases and disorders of mineral metabolism, 2nd ed. New York: Raven Press; 3-9.
3. Lukert BP, Raisz LG. 1990 Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 112:352-364.
4. Hahn TJ, Halstead, LR, Teitelbaum SL, Hahn BH. 1979 Altered mineral metabolism in glucocorticoid-induced osteopenia. J Clin Invest. 64:655-665.
5. Morris HA, Need AG, O'Loughlin PD, Horowitz M, Bridges A, Nordin BEC. 1990 Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int. 46:305-308.
6. 3 and glucocorticoids. Endocrinology. 128:944-950.
7. Hattersley AT, Meeran K, Burrin J, Hill P, Shiner R, Ibbertson HK. 1994 The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels. Calcif Tissue Int. 54:198-202.
8. Urena P, Iida-Klein A, Kong X-F, et al. 1994 Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS17/2.8 and OK cells. Endocrinology. 134:451-456.
9. McSheehy PMG, Chambers TJ. 1986 Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology. 118:824-828.
10. Gronowicz G, McCarthy MB, Raisz LG. 1940 Glucocorticoids stimulate resorption in fetal rat parietal bones in vitro. J Bone Miner Res. 5:1223-1230.
11. Geisterfer M, Richards CD, Gauldie J. 1995 Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130). Cytokine. 7:503-509.
12. Jilka RL, Hangoc G, Girasole G, et al. 1992 Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. 257:88-91.
13. Ray A, LaForge KS, Sehgal PB. 1990 On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (inr motif) occlusion. Mol Cell Biol. 10:5736-5746.
14. Peretz A, Praet J-P, Bosson D, Rozenberg S, Bourdoux P. 1989 Serum osteocalcin in the assessment of corticosteroid induced osteoporosis. Effect of long and short term corticosteroid treatment. J Rheumatol. 16:363-367.
15. Bellows CG, Aubin JE, Heersche JNM. 1987 Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology. 121:1985-1992.
16. Shalhoub V, Conlon D, Tassinari M, et al. 1992 Glucocorticoids promote development of the osteoblast phenotype by selectively modulating expression of cell growth and differentiation associated genes. J Cell Biochem. 50:425-440.
17. Leboy PS, Beresford JN, Devlin C, Owen ME. 1990 Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures. J Cell Physiol. 146:370-378.
18. Delany A, Gabbitas B, Canalis E. 1995 Cortisol down-regulates osteoblast α1 (I) procollagen mRNA by transcriptional and post-transcriptional mechanisms. J Cell Biochem. 57:488-494.
19. Mauviel A. 1993 Cytokine regulation of metalloproteinase gene expression. J Cell Biochem. 53:288-295.
20. Freije JMP, Diez-ltza I, Balbin M, et al. 1994 Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem. 269:16766-16773.
21. Knapuer V, Lopez-Otin C, Smith B, Knight G, Murphy G. 1996 Biochemical characterization of human collagenase-3. Biol Chem. 271:1544-1550.
22. Rifas L, Fausto A, Scott MJ, Avioli LV, Welgus, HG. 1994 Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis. Endocrinology. 134:213-221.
23. Delany AM, Jeffrey JJ, Rydziel S, Canalis E. 1995 Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem. 270:26607-26612.
24. Akerblom IE, Mellon PL. 1991 Repression of gene expression by steroid and thyroid hormones. In: Parker MG, ed. Nuclear hormone receptors: molecular mechanisms, cellular functions, and clinical abnormalities. London: San Diego: Academic Press; 175-196.
25. Beato M, Herrlich P, Schutz G. 1995 Steroid hormone receptors: many actors in search of a plot. Cell. 83:851-857.
26. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AS. 1995 Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 270:283-290.
27. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. 1990 Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science. 249:1266-1272.
28. Morrison N, Eisman J. 1993 Role of the negative glucocorticoid regulatory element in glucocorticoid repression of the human osteocalcin promoter. J Bone Miner Res. 8:969-975.
29. Canalis E, Pash J, Varghese S. 1993 Skeletal growth factors. Crit Rev Eukaryot Gene Expr. 3:155-166.
30. Hock JM, Centrella M, Canalis E. 1988 Insulin-like growth factor I (IGF-I) has independent effects on bone matrix formation and cell replication. Endocrinology. 122:254-260.
31. Canalis E, Rydziel S, Delany AM, Varghese S, Jeffrey JJ. 1995 Insulin-like growth factors inhibit interstitial collagenase synthesis in bone cell cultures. Endocrinology. 136:1348-1354.
32. 2 on bone formation in cultured fetal rat calvariae: role of insulin-like growth factor-I. Endocrinology. 133:1504-1510.
33. McCarthy TL, Centrella M, Canalis E. 1990 Cortisol inhibits the synthesis of insulin-like growth factor-I in skeletal cells. Endocrinology. 126:1569-1575.
34. Delany AM, Canalis E. 1995 Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology. 136:4776-4781.
35. Bennett A, Chen T, Feldman D, Hintz RL, Rosenfeld RG. 1984 Characterization of insulin-like growth factor I receptors on cultured rat bone cells: regulation of receptor concentration by glucocorticoids. Endocrinology. 115:1577-1583.
36. Rydziel S, Canalis E. 1995 Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures. Endocrinology. 136:4254-4260.
37. Nissley P, Kiess W, Sklar M. 1993 Developmental expression IGE-II/mannose-6-phosphate receptor. Mol Reprod Dev. 35:408-413.
38. Lau MMH, Stewart CEH, Liu Z, Bhatt H, Rotwein P, Stewart CL. 1994 Loss of the imprinted 1GF2/cation-independent mannose-6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev. 8:2953-2963.
39. Rechler MM. 1993 Insulin-like growth factor binding proteins. Vitam Horm. 47:1-114.
40. Okazaki R, Riggs BL, Conover CA. 1994 Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells. Endocrinology. 134:126-132.
41. LaTour D, Mohan S, Linkhart TA, Baylink DJ, Strong DD. 1990 Inhibitory insulin-like growth factor-binding protein; cloning, complete sequence, and physiological regulation. Mol Endocrinol. 4:1806-1814.
42. Andress DL, Birnbaum RS. 1992 Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates 1GF action. J Biol Chem. 267:22467-22472.
43. Gabbitas B, Pash JM, Delany AM, Canalis E. 1996 Cortisol inhibits the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures by transcriptional mechanisms. J Biol Chem. 271:9033-9038.
44. Thraikill K, Quarles L, Nigase H, Suzuki K, Serra D, Fowlkes J. 1995 Characterization of insulin-like growth factor binding protein 5-degrading proteases produced throughout murine osteoblast differentiation. Endocrinology. 136:3527-3533.
45. Bach LA, Hsieh S, Sakano K-I, Fujiwara H, Perdue JF, Rechler MM. 1993 Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6. J Biol Chem. 268:9246-9254.
46. Kiefer MC, Schmid C, Waldvogel M, et al. 1992 Characterization of recombinant human insulin-like growth factor binding proteins 4,5, and 6 produced in yeast. J Biol Chem. 267:12692-12699.
47. Gabbitas B, Canalis E. 1996 Cortisol enhances the transcription of insulin-like growth factor binding protein-6 in cultured osteoblasts. Endocrinology. 137:1687-1692.
48. Centrella M, McCarthy TL, Canalis E. 1987 Transforming growth factor Beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem 262:2869-2874.
49. Oursler MJ, Riggs BL, Spelsberg TC. 1993 Glucocorticoid-induced activation of latent transforming growth factor-β by normal human osteoblast-like cells. Endocrinology. 133:2187-2196.
50. 1) activity and binding in osteoblast-enriched cultures from fetal rat bone. Mol Cell Biol. 11:4490-4496.
51. Hock JM, Canalis E. 1994 Platelet-derived growth factor enhances bone cell replication but not differentiated function of osteoblasts. Endocrinology. 134:1423-1428.
52. Canalis E, Centrella M, McCarthy TL. 1988 Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest. 81:1572-1577.
53. Raines EW, Lane TF, Iruela-Arispe ML, Ross R, Sage EH. 1992 The extra-cellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors. Proc Natl Acad Sci USA. 89:1281-1285.
54. Ng KW, Manji SS, Young MF, Findlay DM. 1989 Opposing-influences of glucocorticoid and retinoic acid on transcriptional control in preosteoblasts. Mol Endocrinol. 3:2079-2085.
55. Reid IR, Grey AB. 1993 Corticosteroid osteoporosis. Bailliere Clin Rheumatol. 7:573-587.
56. Jowsey J, Riggs BL. 1970 Bone formation in hypercorrisonism. Acta Endocrinol (Copenh). 68:21-28.
57. Aaron JE, Francis RM, Peacock M, Makins MB. 1989 Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop. 243:294-305.
58. Dempster DW, Arlot MA, Meunier PJ. 1983 Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int. 35:410-417.
59. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M. 1996 Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res. 11:676-685.
60. Johnston Jr CC, Melton III LJ, Lindsay R, Eddy DM. 1989 Clinical indications for bone mass measurements. J Bone Miner Res. 4(Suppl 2).
61. Pocock NA, Eisman JA, Dunstan CR, Evans RA, Thomas DH, Huq NL. 1987 Recovery from steroid-induced osteoporosis. Ann Intern Med. 107:319-323.
62. Lufkin EG, Wahner HW, Bergstralh E. 1988 Reversibility of steroid-induced osteoporosis. Am J Med. 85:887-888.
63. Toogood JH, Baskerville JC, Markov AE, et al. 1995 Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol. 96:157-166.
64. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM. 1992 Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax. 47:414-417.
65. Gennari C, Imbimbo B. 1985 Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int. 37:592-593.
66. Canalis E, Avioli L. 1992 Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells. J Bone Miner Res. 7:1085-1092.
67. Sambrook P, Birmingham J, Kelly P, et al. 1993 Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med. 328:1747-1752.
68. Luengo M, Pons F, Martinez de Osaba MJ, Picado C. 1994 Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax. 49:1099-1102.
69. Strays A, Snelder AA, Mulder H. 1995 Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med. 99:235-242.
70. Diamond T, McGuigan L, Barbagallo S, Bryant C. 1995 Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med. 98:459-463.
71. Mulder H, Struys A. 1994 Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol. 33:348-350.
72. Liberman UA, Weiss SR, Broll J, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1437-1443.
73. Lukert BP, Johnson BE, Robinson RG. 1992 Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res. 7:1063-1069.
74. Rizzoli R, Chevalley T, Slosman DO, Bonjour J-P. 1995 Sodium monofluorophosphate increases vertebral bone mineral density in patients with corticosteroid-induced osteoporosis. Osteoporosis Int. 5:39-46.
75. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. 1995 Treatment of postmenopausal osteoporosis with slow-release sodium flouride. Final report of a randomized controlled trial. Ann Intern Med. 123:401-408.
76. Clemmons DR. 1992 Editorial: role of insulin-like growth fartor-I in reversing catabolism. J Clin Endocrinol Metab. 75:1183-1196.
77. Ebeling PR, Jones JD, O'Fallon WM, Janes CH, Riggs BL. 1993 Short-term effects of recombinant human insulin-like growth factor-I on bone turnover in normal women. J Clin Endocrinol Metab. 77:1384-1387.
78. Grinspoon SK, Baum HBA, Peterson S, Kilbanski A. 1995 Effects of rhIGF-I administration on bone turnover during short-term fasting. J Clin Invest. 96:900-906.
79. Chiron LJ, Thompson JL, Holloway L, et al. 1995 Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res. 10:1844-1852.
80. Narusatva KI, Nakamura T, Suzuki K, et al. 1995 The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res. 10:1853-1864.
81. Canalis E. 1995 Growth hormone, skeletal growth factors and osteoporosis. Endocr Pract. 1:39-43.
82. Ortoft G, Bruel A, Andreassen TT, Oxlund H. 1995 Growth hormone is not able to counteract osteopenia of rat cortical bone induced by glucocorticoid with protracted effect. Bone. 17:543-548.
83. Canalis E, Centrella M, Burch M, McCarthy TL. 1989 Insulin-like growth factor I mediates selected anabolic effects of parathyroid hormone in bone cultures. J Clin Invest, 83:60-65.
84. Finkelstein JS, Klibanski A, Schaefer EH, Homstein MD, Schiff I, Neer RM. 1994 Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med. 331:1618-1623.
85. Schmidt IU, Dobnig H, Turner RT. 1995 Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology. 136:5127-5134.